<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060826</url>
  </required_header>
  <id_info>
    <org_study_id>2008-003338-41</org_study_id>
    <secondary_id>2008-003338-41</secondary_id>
    <nct_id>NCT01060826</nct_id>
  </id_info>
  <brief_title>Efficacy of Administration of Somatostatin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis</brief_title>
  <acronym>crepsmt1</acronym>
  <official_title>Randomized, Double-blind Study to Evaluate the Efficacy of Administration With Intravenous Bolus Followed by a Continuous Infusion of Somatostatin in the Prevention of Post-ERCP Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis is the most frequent (5-10%) and severe complication after endoscopic
      retrograde cholangiopancreatography (ERCP), that could require of surgical intervention and
      lead to death. A double- blind study designed to evaluate if the treatment with somatostatin
      in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for
      4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted
      to ERCP will be randomized in two groups of treatment, one will receive somatostatin and
      another placebo. The main aim of this study will be the incidence of acute post-ERCP
      pancreatitis and secondary objectives will be identify sub-groups of patient with high risk
      to develop post-ERCP pancreatitis, who could benefit of pharmacologic prophylaxis before the
      exploration. The study will include 510 patients submitted to an ERCP during a period of 3
      years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double- blind study designed to evaluate if the treatment with somatostatin in intravenous
      bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after
      endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will
      be randomized in two groups of treatment, one will receive somatostatin and another placebo.
      The main aim of this study will be the incidence of acute post-ERCP pancreatitis and
      secondary objectives will be identify sub-groups of patient with high risk to develop
      post-ERCP pancreatitis, who could benefit of pharmacologic prophylaxis before the
      exploration. The study will include 510 patients submitted to an ERCP during a period of 3
      years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of acute post-ERCP pancreatitis</measure>
    <time_frame>One week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify sub-groups of patients with high risk to develop post-ERCP pancreatitis</measure>
    <time_frame>One week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>somatostatin, intravenous bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, intravenous bolus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fisiologic serum</intervention_name>
    <description>250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure</description>
    <arm_group_label>Placebo, intravenous bolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatostatin, intravenous bolus</intervention_name>
    <description>250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic</description>
    <arm_group_label>somatostatin, intravenous bolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatostatin</intervention_name>
    <description>Intravenous bolus 250 micrograms</description>
    <arm_group_label>somatostatin, intravenous bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients undergoing therapeutic endoscopic retrograde cholangiopancreatography (ERCP).

        Exclusion Criteria:

          1. Pregnancy or history of allergy to somatostatin.

          2. Acute myocardial infarction within 3 months of the procedure.

          3. Acute pancreatitis in patients undergoing early ERCP in the acute phase of the
             disease.

          4. Previous sphincterotomy.

          5. Chronic pancreatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Gómez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endoscopy Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endoscopy Unit Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Guarner</last_name>
      <email>cguarner@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Cristina Gómez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Gómez</last_name>
      <phone>620936011</phone>
      <email>cgomezo@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Cristina Gómez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gastro.org</url>
    <description>preventing post-therapeutic ERCP pancreatitis</description>
  </link>
  <reference>
    <citation>1. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-93. 2. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004;59:845-64. 3. Bordás JM et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 1998;47:230-4. 4. Poon RT, Yeung C, Liu CL, et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomized controlled trial. Gut 2003;52:1768-73. 5. Andriulli A et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc. 2000;5:1-7.</citation>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cristina Gómez Oliva (principal investigator)</name_title>
    <organization>Cristina Gómez</organization>
  </responsible_party>
  <keyword>acute pancreatits</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

